These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35898799)

  • 1. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

  • 2. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
    Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
    EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
    Stegmann KM; Dickmanns A; Heinen N; Blaurock C; Karrasch T; Breithaupt A; Klopfleisch R; Uhlig N; Eberlein V; Issmail L; Herrmann ST; Schreieck A; Peelen E; Kohlhof H; Sadeghi B; Riek A; Speakman JR; Groß U; Görlich D; Vitt D; Müller T; Grunwald T; Pfaender S; Balkema-Buschmann A; Dobbelstein M
    iScience; 2022 May; 25(5):104293. PubMed ID: 35492218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19).
    Pagliano P; Sellitto C; Ascione T; Scarpati G; Folliero V; Piazza O; Franci G; Filippelli A; Conti V
    Expert Opin Drug Discov; 2022 Dec; 17(12):1299-1311. PubMed ID: 36508255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat.
    Chang CH; Peng WY; Lee WH; Yang L; Lin TY; Yang MH; Tsai TH
    Commun Med (Lond); 2023 Oct; 3(1):150. PubMed ID: 37857815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.
    Kiy RT; Khoo SH; Chadwick AE
    Toxicol Res (Camb); 2024 Feb; 13(1):tfae012. PubMed ID: 38328743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.
    Teli D; Balar P; Patel K; Sharma A; Chavda V; Vora L
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.
    Marikawa Y; Alarcon VB
    Reprod Toxicol; 2023 Oct; 121():108475. PubMed ID: 37748715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
    Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Nanopore Based Molnupiravir Sensor.
    Jia W; Hu C; Wang Y; Zhang P; Chen HY; Huang S
    ACS Sens; 2022 May; 7(5):1564-1571. PubMed ID: 35427117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
    Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
    J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry.
    Urbanowicz K; Opielka M; Stegmann KM; Dickmanns A; Dobbelstein M; Peters GJ; Smoleński RT
    Nucleosides Nucleotides Nucleic Acids; 2024 May; ():1-9. PubMed ID: 38741480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody.
    Zibat A; Zhang X; Dickmanns A; Stegmann KM; Dobbelstein AW; Alachram H; Soliwoda R; Salinas G; Groß U; Görlich D; Kschischo M; Wollnik B; Dobbelstein M
    iScience; 2023 Oct; 26(10):107786. PubMed ID: 37731621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.